SGLT2 Inhibitors Are Associated With Suppression of the Sema3A / NRP1 /Plexin‐ A1 Signaling Axis in Postmenopausal Women With Type 2 Diabetes: Evidence From Propensity Score‐Matched Analysis
Journal of Diabetes · 2026
DOI: 10.1111/1753-0407.70262 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Diabetes, 2026. Verfasst von Sertas Erarslan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Faculty of Medicine, Kütahya Health Sciences University, Kutahya, Turkey. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Signal Transduction, Neuropilin-1, Semaphorin-3A. Die Arbeit nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Faculty of Medicine, Kütahya Health Sciences University, Kutahya, Turkey.
ORCID-Profile: Sertas Erarslan, Burcu Cosgun Bora
Zitieren
APA
Erarslan, S., & Bora, B. C. (2026). SGLT2 Inhibitors Are Associated With Suppression of the Sema3A / NRP1 /Plexin‐ A1 Signaling Axis in Postmenopausal Women With Type 2 Diabetes: Evidence From Propensity Score‐Matched Analysis. Journal of Diabetes. https://doi.org/10.1111/1753-0407.70262
Vancouver
Erarslan S, Bora BC. SGLT2 Inhibitors Are Associated With Suppression of the Sema3A / NRP1 /Plexin‐ A1 Signaling Axis in Postmenopausal Women With Type 2 Diabetes: Evidence From Propensity Score‐Matched Analysis. Journal of Diabetes. 2026. doi:10.1111/1753-0407.70262
BibTeX
@article{Erarslan2026,
author = {Erarslan, Sertas and Bora, Burcu Cosgun},
title = {SGLT2 Inhibitors Are Associated With Suppression of the Sema3A / NRP1 /Plexin‐ A1 Signaling Axis in Postmenopausal Women With Type 2 Diabetes: Evidence From Propensity Score‐Matched Analysis},
journal = {Journal of Diabetes},
year = {2026},
doi = {10.1111/1753-0407.70262}
}
EUVIMED